{
  "url": "https://www.benzinga.com/pressreleases/25/08/g47297576/praxis-alert-bragar-eagel-squire-p-c-is-investigating-praxis-precision-medicines-inc-on-behalf-of-",
  "authorsByline": "Globe Newswire",
  "articleId": "bf0ecd0398bf4aa895fc0b5e8249ba1c",
  "source": {
    "domain": "benzinga.com",
    "paywall": false,
    "location": {
      "country": "us",
      "state": "MI",
      "county": "Wayne County",
      "city": "Detroit",
      "coordinates": {
        "lat": 42.3315509,
        "lon": -83.0466403
      }
    }
  },
  "imageUrl": "http://benzinga.com/next-assets/images/schema-image-default.png",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-23T09:32:00-04:00",
  "addDate": "2025-08-23T13:45:41.899292+00:00",
  "refreshDate": "2025-08-23T13:45:41.899295+00:00",
  "score": 1.0,
  "title": "PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm - Praxis Precision Medicine (NASDAQ:PRAX)",
  "description": "Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Praxis",
  "content": "Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired stock in Praxis and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.\n\nNEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (\"Praxis\" or the \"Company\") PRAX on behalf of Praxis stockholders. Our investigation concerns whether Praxis has violated the federal securities laws and/or engaged in other unlawful business practices.\n\nClick here to participate in the action.\n\nOn August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study.\n\nOn this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025.\n\nIf you purchased or otherwise acquired Praxis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.\n\nBragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes.\n\nFollow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.",
  "medium": "Article",
  "links": [
    "https://www.globenewswire.com/Tracker?data=yk3_iI07jkXLeQQsxmreAXm7hJPKzYHtL9qQyQc9GJIDs6EGZsiMNU_Mm_mJbag2HaJJT6x0wX-GSvyslR-df453-sPTfqgicMfHELfLLxH6nSkAJkqpP9JTq3tacIij",
    "https://www.globenewswire.com/Tracker?data=YN9YpfxOyLCgQ-zdWZzSlvJv2E12vkXnQAc0QzsyEViGNHLSbE92Q7Oph9I_8aKvqZwuapgIzNgFX3_sKEjp6ByvDSpRVf7xNyeIyC42PsSzFTximz9woWm7Etq5XUP5",
    "https://www.globenewswire.com/Tracker?data=PFP8o6LBliGRHaB41JUftodNmAvzXDnP66SyPRcb-zZ7UAAFmQah1XkeEBCiP3lWMCaNxFF1nWuvkWdR5nYjWw==",
    "https://www.globenewswire.com/Tracker?data=8jFnuGR65MSQXFPt5rBV9ffCiy_kycbcSWNbHFVS5PMjMnFXUjIju2CE6WyacLCH2LsCTt76PwcFzuATU0v4_mDLoXn21ZA6Fz8oj3cKFA1C9PwWasBS7g2kyFX9intP",
    "https://www.globenewswire.com/Tracker?data=UKynm4jC_Igw7RK1_Xsgn3suUML2Y02qTRt7mLNWb4rW39UZdxdo5qaFfmGgwvgLmzfIK0f9_4xt0OkeKciRITgcJrcX_3ApYrvwHPXvVPOM7jj5GOxYje5xifAZxuDh",
    "https://www.globenewswire.com/Tracker?data=cnUq1PCE6hEP3_Nhck2cBRtWZOK74sQSHPzZRLnTgVdKmxjdGon6WEa1P4yP-IngYKRz1iFOCX40u6DnRFa2WA==",
    "https://www.globenewswire.com/Tracker?data=s6XdkFVi0-s4fCa6OBfhFUhgHUI0D2AkKEF48bafgcEtlF6STZS8TT8DoJt3jDMwvgbpSuGjn4DnZHq1Tl6ZFA==",
    "https://www.globenewswire.com/Tracker?data=8jFnuGR65MSQXFPt5rBV9WNRhmlm2XslpPUoR4C2Lztv-E6JfBgYb8FcxmOglVdEAwDHOXEZFFDFh0_LvXLNvHr8MDCBVufQQMyByHHwp8Lqf_n416Uu0V8RJk-wuKqs",
    "https://www.globenewswire.com/Tracker?data=PFP8o6LBliGRHaB41JUftkOY4u-rP9e0Do-ZrsD2oUI_l5XTF2PAhGDOxK40kqXGLrj_FwHcBAuUxO1Phk36XA==",
    "https://www.globenewswire.com/Tracker?data=UKynm4jC_Igw7RK1_XsgnwjNgjhaUFcXZ4OiiVr6IGV8KqRh1HQRJdmHilVGfUFSzdT4HjCyCauoopaAfJJDSuenm50eE_hWnZQAeOWRuHavkunWvwlsVJJNMx-ZzEJ5",
    "https://www.globenewswire.com/Tracker?data=4k7HsJdydBiVffIQwOtR2GTKcxb2IV0hWPS40DNFOcAMYQx6f3r6di01uzRjrcv5FbOtTqNWNjv2-Y6GpT2D6XDqm9Q3z6MTsoBFkz_f0_T_KEvILeKMBqCLJI36aq1N",
    "https://www.globenewswire.com/Tracker?data=Vbw4BPWSSR5hKZXlCW6ChPv_i91Lb-V7dx6BqpoLkrCivBCq4FjDZzc-yOu6eYI4F1Pz62wxBoPNRz_zkqIZAkeZ6Z3adpinqfWrlKJbS2Y=",
    "https://www.globenewswire.com/Tracker?data=4k7HsJdydBiVffIQwOtR2GTKcxb2IV0hWPS40DNFOcAmqVK5F-ONhY6MzhSwGSvDHMhzPC_AC_XHB1cpLlxuTdffq9L83pANWzmOHHZ6EblUr-W1kjouoDK6UsgrZOmM",
    "https://www.globenewswire.com/Tracker?data=_AE6OgWZ6l1e97eWvFanXmKj-5PS-RKaT1_mdPT-tZLlot9yfViWLZQEsvPE7yCKs-yMKU0-zJVYwIYeuyqqMk9rXui6eEAR2Gzy1HPCzOuiAlaYFS8uy7Hlv5ei63-T",
    "https://www.globenewswire.com/Tracker?data=YB37cspnbi_jX30Rbd61FS9N-1gdmauMa7uVwYZnAPtmuZal9E5eGSpoviUuZJUXEhGTAD89qDgMyZzoWiZxQw==",
    "https://www.globenewswire.com/NewsRoom/AttachmentNg/29481954-f2ff-4756-b5a9-d982a6497bd0"
  ],
  "labels": [
    {
      "name": "Press Release"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Praxis Stockholders",
      "weight": 0.104057215
    },
    {
      "name": "Praxis stockholders",
      "weight": 0.104057215
    },
    {
      "name": "Praxis shares",
      "weight": 0.10022201
    },
    {
      "name": "Praxis Precision Medicines",
      "weight": 0.099056326
    },
    {
      "name": "Praxis Precision Medicine",
      "weight": 0.096296124
    },
    {
      "name": "Praxis",
      "weight": 0.09381143
    },
    {
      "name": "Brandon Walker",
      "weight": 0.083451346
    },
    {
      "name": "mid-stage study results",
      "weight": 0.080577955
    },
    {
      "name": "other news",
      "weight": 0.072545774
    },
    {
      "name": "Bragar Eagel",
      "weight": 0.070926294
    }
  ],
  "topics": [
    {
      "name": "Markets"
    },
    {
      "name": "Stocks"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.9912109375
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.97607421875
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97314453125
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.7626953125
    },
    {
      "name": "/Law & Government/Legal/Other",
      "score": 0.55615234375
    },
    {
      "name": "/Finance/Investing/Other",
      "score": 0.49951171875
    },
    {
      "name": "/Law & Government/Legal/Legal Services",
      "score": 0.48583984375
    },
    {
      "name": "/Law & Government/Legal/Business & Corporate Law",
      "score": 0.396484375
    }
  ],
  "sentiment": {
    "positive": 0.08885234,
    "negative": 0.45056894,
    "neutral": 0.46057868
  },
  "summary": "Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (PRAX), regarding federal securities laws and/or unlawful business practices. The firm's partner, Brandon Walker, has encouraged investors to contact him directly to discuss their legal options. The investigation is focused on whether Praxxis has violated federal Securities laws or engaged in other unlawful practices. On August 4, 2025, the company's stock price fell by 5.55% to close at $51.09 per share.",
  "shortSummary": "Bragar Eagel & Squire is investigating Praxis Precision Medicines for potential securities violations, following a 5.55% drop in its share price.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "20a3fc1aa2c8447fabc8fa3e965f051a",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.globenewswire.com/Tracker?data=PFP8o6LBliGRHaB41JUftodNmAvzXDnP66SyPRcb-zZ7UAAFmQah1XkeEBCiP3lWMCaNxFF1nWuvkWdR5nYjWw==",
      "text": "Court Approves Settlement, Align Technology, Inc. to Implement Key Reforms\nBragar Eagel & Squire, P.C. is excited to share news of a settlement on behalf of Align Technology, Inc.'s shareholders. Today, February 5, 2025, United States District Court Judge Trina L. Thompson approved the global settlement as final. This is the result of extensive negotiations by Bragar Eagel & Squire, P.C., together with co-counsel. The settlement will require key corporate governance reforms, including adding an independent director with cybersecurity expertise to the Board, enhanced Board trainings, and enhanced regulatory compliance and compliance oversight functions. These reforms should help protect the Align Technology, Inc.\u2019s investors in the future.\n*Past results do not guarantee future outcomes.\nLinkedIn"
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=UKynm4jC_Igw7RK1_XsgnwjNgjhaUFcXZ4OiiVr6IGV8KqRh1HQRJdmHilVGfUFSzdT4HjCyCauoopaAfJJDSuenm50eE_hWnZQAeOWRuHavkunWvwlsVJJNMx-ZzEJ5",
      "text": "Please join us in welcoming Jack Sanner to Bragar Eagel & Squire, P.C. as our newest Attorney! Jack joined the team after completing a prestigious position as a judicial law clerk for the Honorable Andrea M. Leahy of the Appellate Court of Maryland. He is licensed to practice law in Massachusetts and is currently seeking admission in New York. We're excited to have Jack bring his credentials, skills, and enthusiasm to support our clients and fight for justice. Welcome aboard! #NewTeamMember #Welcome #bragareagelandsquire #brandonwalker\nAbout us\nBragar Eagel & Squire, P.C. is an established law firm that excels at litigating complex actions in any venue. We focus our practice on corporate law litigation, including shareholders\u2019 rights, derivative actions, and federal securities claims. We also have robust practices litigating consumer class actions, antitrust, real estate, bankruptcy and general commercial litigation. Our firm has an active practice in the Delaware Court of Chancery, and our attorneys have achieved significant successes before the Delaware Supreme Court. We litigate in federal courts across the country, and our state court practice spans from New York to Hawaii. Our attorneys have developed wide-ranging expertise, from complex Master Limited Partnership transactions, to consumer promotions, to Internet privacy concerns. Our attorneys have decades of experience representing investors and consumers in complex litigations on a national and local scale. We work with each client to understand its unique needs and develop the proper strategy to obtain its goals.\n- Website\n-\nhttp://bespc.com/\nExternal link for Bragar Eagel & Squire, P.C.\n- Industry\n- Legal Services\n- Company size\n- 11-50 employees\n- Headquarters\n- New York, NY\n- Type\n- Privately Held\nLocations\n-\nPrimary\nGet directions\n885 Third Avenue, Suite 3040\nNew York, NY 10022, US\nEmployees at Bragar Eagel & Squire, P.C.\nUpdates\n-\nBragar Eagel & Squire, P.C. Files Data Breach Lawsuit On July 25, 2025, Bragar Eagel & Squire, P.C. filed a data breach class action in a Virginia federal court. The lawsuit is against Radiology Associates of Richmond, Inc. for a data breach that occurred between April 2, 2024 and April 6, 2024. Follow us for more developments. #BES #bragareagelandsquire #BrandonWalker #getdataprivacyhelp\n-\nBragar Eagel & Squire, P.C. is proud to support Girls on the Run New Orleans and its incredible work in the community! As a firm, we believe in giving back to the organizations that make a real difference in the lives of our neighbors. Thank you to the amazing team at Girls on the Run New Orleans for all you do. #BES #bragareagelandsquire #BrandonWalker #GivingBack #neworleans\n-\nBragar Eagel & Squire, P.C. Attorney, Casey DeReus, has been appointed to serve on the Committee on the Profession (2025-2026) by the Louisiana State Bar Association! This prestigious appointment recognizes her dedication to upholding the highest standards of legal practice and commitment to advancing the profession in Louisiana. The Committee on the Profession plays a vital role in maintaining professional excellence and integrity within our legal community. Congratulations, Casey! #BES #bragareagelandsquire #LSBA #LegalProfession\n-\nHappy Independence Day from the whole Bragar Eagel & Squire, P.C. Team! #bes #bragareagelandsquire #brandonwalker #4thofJuly #america\n-\nBragar Eagel and Squire, P.C. Partner, Brandon Walker, has been named one of the \u201cMost Influential Lawyers of 2025\u201d by Lawyers of Distinction. Well-deserved, Brandon! Keep up the great work! #BES #bragareagelandsquire #brandonwalker #LawyerOfDistinction\n-\nWhen legal minds from across the nation come together, great things happen. Bragar Eagel and Squire, P.C. has attorneys from coast-to-coast. This week, the attorneys converged in New York for strategic planning and collaboration. Team members brought diverse perspectives and shared expertise to the table. These face-to-face connections strengthen our ability to serve clients nationwide with the dedication and excellence they deserve. Here's to building stronger partnerships and delivering even better results together. \ud83d\udcbc\u2696\ufe0f #BES #bragareagelandsquire #brandonwalker #Collaboration #Teamwork\n-\nLOVESAC SETTLEMENT UPDATE Major corporate governance win! The Lovesac Company has agreed to implement comprehensive reforms including: -New Disclosure Committee for financial oversight -Enhanced CFO/General Counsel responsibilities -Enhanced Audit Committee duties -Director & employee education & training -Improved internal controls & compliance functions These 4-year reforms address financial reporting issues and benefit all shareholders. Court approval is still pending. Bragar Eagel and Squire, P.C. is proud to have assisted co-lead counsel in achieving this milestone. hashtag #bes #bragareagelandsquire #brandonwalker #ShareholderRights #Lovesac *Past results do not guarantee future outcomes.\n-\n\ud83c\udf89 Please join us in welcoming Madeleine Fitzhenry to our legal team as our newest Paralegal! We're excited to have her bring her skills and enthusiasm to support our clients and strengthen our practice. Welcome aboard! #NewTeamMember #Welcome #bragareagelandsquire #brandonwalker\n-\nToday, Bragar Eagel & Squire, P.C. joins the rest of America in solemn observance of America\u2019s fallen heroes. The sacrifice these heroes made for freedom will never be forgotten. #bragareagelandsquire #brandonwalker #memorialday #honor #freedom"
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=8jFnuGR65MSQXFPt5rBV9ffCiy_kycbcSWNbHFVS5PMjMnFXUjIju2CE6WyacLCH2LsCTt76PwcFzuATU0v4_mDLoXn21ZA6Fz8oj3cKFA1C9PwWasBS7g2kyFX9intP",
      "text": "Bio\nLegal Career\n- 2014-2015 Partner, Kirby McInerney LLP\n- 2012-2014 Associate, Kirby McInerney LLP\n- 2008-2012 Associate, Motley Rice LLC\nAreas of Practice\nBrandon has a broad background in securities fraud, corporate governance and other complex class action and commercial litigation on behalf of shareholders. He has represented public retirement systems, union pension funds, European investment managers, and other institutional and individual investors before federal, state, and appellate courts throughout the country.Professional Activities and Associations\n- New York State Bar Association\n- South Carolina Bar Association\n- South Carolina Bar TIPS General Council (2025-2028)\nhttps://youtu.be/RSqtEMdVqHQ\nExperience\n- Wagner v. Third Avenue Management LLC, et al., C.A. No. 12184-VCL (Del. Ch.). Co-lead counsel in derivative action challenging alleged mismanagement of Third Avenue Trust by Third Avenue Management LLC. Settled for $25 million.\n- In re Cornerstone Therapeutics Inc. Stockholder Litigation, Cons. C.A. No. 8922-VCG (Del. Ch.). Co-lead counsel in action challenging the acquisition of Cornerstone by Chiesi Farmaceutici S.p.A. Settled for $17.88 million in additional compensation to unaffiliated shareholders.\n- In re BP p.l.c. Securities Litigation, Case No. 4:10-md-2185 (S.D. Tex.). Representation of nine European investment managers in individual securities fraud actions pursuant to English law against BP p.l.c. related to the Deepwater Horizon disaster on April 20, 2010.\n- Stein v. Match Group, Inc., et al., Case No. 3:16-cv-00549-L (N.D. Tex.). Co-lead counsel in action challenging alleged materially false and misleading statements in the Prospectus and Registration Statement filed by Match Group in connection with its Initial Public Offering.\n- Forsythe v. Nantkwest, Inc., et al., Case No. 2:16-cv-03438 (C.D. Cal.). Co-lead counsel in action challenging alleged materially false and misleading statements about the company\u2019s accounting practices and internal controls.\n- In re Supreme Industries, Inc. Securities Litigation, Case No. 3:17-cv-143-TLS-MGG (N.D. Ind.). Co-lead counsel in action challenging alleged materially false and misleading statements about the company\u2019s order backlog as proof of strong order activity.\n- Crago v. Charles Schwab & Co., Inc., and the Charles Schwab Corporation, Case No. 3:16-cv-03938-RS (N.D. Cal.). Co-lead counsel in action challenging allegedly false and misleading statements regarding Schwab\u2019s practice of receiving payments for order flow.\n- Ross and Parker v. Rh\u00f4ne Capital, L.L.C. et al., Case No. CACE-16-013220 (Cir. Ct. 17th Jud. Dist., Broward Cty., Fla.). Co-lead counsel in action challenging the acquisition of Elizabeth Arden by Revlon.\n- Shupak v. Reed, et al., Case No. BC617444 (Cal. Super Ct., Los Angeles Cty.). Derivative action challenging alleged breaches of good faith, loyalty, and candor by officers and directors of Sempra Energy and SoCalGas related to the Porter Ranch/Aliso Canyon gas leak.\n- In re Allion Healthcare, Inc. Shareholders Litigation, C.A. No. 5022-CC (Del. Ch.). Co-lead counsel in action challenging a going-private transaction whereby Allion merged with H.I.G. Capital Inc. and a group of Allion stockholders. The action was settled with a $4 million payment to Allion\u2019s unaffiliated shareholders and additional disclosures to shareholders.\n- In re RehabCare Group, Inc., Shareholders Litigation, C.A. No. 6197-VCL (Del. Ch.). Co-lead counsel in action challenging the acquisition of RehabCare by Kindred Healthcare, Inc. which resulted in a $2.5 million payment to RehabCare shareholders, modification of the merger agreement, and additional disclosures to shareholders.\n- In re Atheros Communications Shareholder Litigation, C.A. No. 6124-VCN (Del. Ch.). Co-lead counsel in action challenging the acquisition of Atheros by Qualcomm Incorporated which resulted in the issuance of a preliminary injunction by the Delaware Court of Chancery delaying the shareholder vote and requiring additional disclosures to shareholders.\n- Maric Capital Master Fund, Ltd. v. PLATO Learning, Inc., C.A. No. 5402-VCS (Del. Ch.). Lead counsel in action challenging the acquisition of PLATO by Thoma Bravo, LLC which resulted in the issuance of a preliminary injunction by the Delaware Court of Chancery requiring additional disclosures to shareholders.\nCases\nCincinnati Bell, Inc.\nU.S. District Court: Southern District of New YorkTelaria, Inc.\nU.S. District Court: Northern CaliforniaDiplomat Pharmacy, Inc.\nU.S. District Court: Eastern District of MichiganAK Steel Holding Corporation\nU.S. District Court: Eastern District of MichiganSORL Auto Parts, Inc.\nU.S. District Court: Southern District of New YorkAircastle Limited\nU.S. District Court: Southern District of New YorkSlack Technologies, Inc. (NYSE: WORK)\nU.S. Court of Appeals: Ninth CircuitEmpire Resorts, Inc.\nCourt of Chancery of the State of DelawareVitamin Shoppe, Inc.\nCourt of Chancery of the State of DelawareCarrizo Oil & Gas, Inc.\nU.S. District Court: Southern District of New YorkHighpower International, Inc.\nIsramco, Inc.\nAkers Biosciences, Inc. (AKER)\nAlnylam Pharmaceuticals, Inc. (ALNY)\nZebra Technologies Corporation\nU.S. District Court: District of Northen IllinoisOSI Systems, Inc. (NASDAQ: OSIS)\nU.S. District Court: Central CaliforniaAqua Metals, Inc. (NASDAQ: AQMS)\nU.S. District Court: District of DelawareEquifax Inc. (EFX)\nU.S. District Court: Northern GeorgiaNews\nInvestors Reach a $12 Million Settlement in NantKwest Stock Drop Lawsuit\nBragar Eagel & Squire, P.C. announces that it has filed papers with the United States District Court to approve a $12 million settlement of a shareholder class action alleging that NantKwest failed to disclose tens of millions of dollars of executive compensation prior to its 2015 initial public offering. Bragar Eagel & Squire, P.C., and its co-counsel have vigorously litigated this action on behalf of the class for over two years.\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nBragar Eagel & Squire, P.C. appointed Lead Counsel in Shah v. A10 Networks, Inc. et al.\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nBragar Eagel & Squire, P.C. appointed Lead Counsel in Xu v. Gridsum Holding Inc. et al., No. 18 Civ. 3655\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nU.S. District Court Judge Richard Seeborg of the United States District Court for the Northern District of California denied Charles Schwab\u2019s motion to dismiss in Crago v. Charles Schwab & Co., Inc\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nU.S. District Judge Michael W. Fitzgerald of the United States District Court for the Central District of California denies NantKwest\u2019s motion to dismiss in Sudunagunta v. NantKwest, Inc\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nBragar Eagel & Squire, P.C. appointed Co-Lead Counsel in the action Sudunagunta v. NantKwest, Inc.\nFor additional information, please contact Brandon Walker, Esq. at (212) 355-4648.\nPrior results do not guarantee a similar outcome.\nBragar Eagel & Squire, P.C. appointed Co-Lead Counsel in McCloskey v. Match Group, Inc.\nFor additional information, please contact Brandon Walker, Esq. at (212) 355-4648.\nPrior results do not guarantee a similar outcome."
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=8jFnuGR65MSQXFPt5rBV9WNRhmlm2XslpPUoR4C2Lztv-E6JfBgYb8FcxmOglVdEAwDHOXEZFFDFh0_LvXLNvHr8MDCBVufQQMyByHHwp8Lqf_n416Uu0V8RJk-wuKqs",
      "text": "Bio\nLegal Career\n- 2014-2015 Partner, Kirby McInerney LLP\n- 2012-2014 Associate, Kirby McInerney LLP\n- 2008-2012 Associate, Motley Rice LLC\nAreas of Practice\nBrandon has a broad background in securities fraud, corporate governance and other complex class action and commercial litigation on behalf of shareholders. He has represented public retirement systems, union pension funds, European investment managers, and other institutional and individual investors before federal, state, and appellate courts throughout the country.Professional Activities and Associations\n- New York State Bar Association\n- South Carolina Bar Association\n- South Carolina Bar TIPS General Council (2025-2028)\nhttps://youtu.be/RSqtEMdVqHQ\nExperience\n- Wagner v. Third Avenue Management LLC, et al., C.A. No. 12184-VCL (Del. Ch.). Co-lead counsel in derivative action challenging alleged mismanagement of Third Avenue Trust by Third Avenue Management LLC. Settled for $25 million.\n- In re Cornerstone Therapeutics Inc. Stockholder Litigation, Cons. C.A. No. 8922-VCG (Del. Ch.). Co-lead counsel in action challenging the acquisition of Cornerstone by Chiesi Farmaceutici S.p.A. Settled for $17.88 million in additional compensation to unaffiliated shareholders.\n- In re BP p.l.c. Securities Litigation, Case No. 4:10-md-2185 (S.D. Tex.). Representation of nine European investment managers in individual securities fraud actions pursuant to English law against BP p.l.c. related to the Deepwater Horizon disaster on April 20, 2010.\n- Stein v. Match Group, Inc., et al., Case No. 3:16-cv-00549-L (N.D. Tex.). Co-lead counsel in action challenging alleged materially false and misleading statements in the Prospectus and Registration Statement filed by Match Group in connection with its Initial Public Offering.\n- Forsythe v. Nantkwest, Inc., et al., Case No. 2:16-cv-03438 (C.D. Cal.). Co-lead counsel in action challenging alleged materially false and misleading statements about the company\u2019s accounting practices and internal controls.\n- In re Supreme Industries, Inc. Securities Litigation, Case No. 3:17-cv-143-TLS-MGG (N.D. Ind.). Co-lead counsel in action challenging alleged materially false and misleading statements about the company\u2019s order backlog as proof of strong order activity.\n- Crago v. Charles Schwab & Co., Inc., and the Charles Schwab Corporation, Case No. 3:16-cv-03938-RS (N.D. Cal.). Co-lead counsel in action challenging allegedly false and misleading statements regarding Schwab\u2019s practice of receiving payments for order flow.\n- Ross and Parker v. Rh\u00f4ne Capital, L.L.C. et al., Case No. CACE-16-013220 (Cir. Ct. 17th Jud. Dist., Broward Cty., Fla.). Co-lead counsel in action challenging the acquisition of Elizabeth Arden by Revlon.\n- Shupak v. Reed, et al., Case No. BC617444 (Cal. Super Ct., Los Angeles Cty.). Derivative action challenging alleged breaches of good faith, loyalty, and candor by officers and directors of Sempra Energy and SoCalGas related to the Porter Ranch/Aliso Canyon gas leak.\n- In re Allion Healthcare, Inc. Shareholders Litigation, C.A. No. 5022-CC (Del. Ch.). Co-lead counsel in action challenging a going-private transaction whereby Allion merged with H.I.G. Capital Inc. and a group of Allion stockholders. The action was settled with a $4 million payment to Allion\u2019s unaffiliated shareholders and additional disclosures to shareholders.\n- In re RehabCare Group, Inc., Shareholders Litigation, C.A. No. 6197-VCL (Del. Ch.). Co-lead counsel in action challenging the acquisition of RehabCare by Kindred Healthcare, Inc. which resulted in a $2.5 million payment to RehabCare shareholders, modification of the merger agreement, and additional disclosures to shareholders.\n- In re Atheros Communications Shareholder Litigation, C.A. No. 6124-VCN (Del. Ch.). Co-lead counsel in action challenging the acquisition of Atheros by Qualcomm Incorporated which resulted in the issuance of a preliminary injunction by the Delaware Court of Chancery delaying the shareholder vote and requiring additional disclosures to shareholders.\n- Maric Capital Master Fund, Ltd. v. PLATO Learning, Inc., C.A. No. 5402-VCS (Del. Ch.). Lead counsel in action challenging the acquisition of PLATO by Thoma Bravo, LLC which resulted in the issuance of a preliminary injunction by the Delaware Court of Chancery requiring additional disclosures to shareholders.\nCases\nCincinnati Bell, Inc.\nU.S. District Court: Southern District of New YorkTelaria, Inc.\nU.S. District Court: Northern CaliforniaDiplomat Pharmacy, Inc.\nU.S. District Court: Eastern District of MichiganAK Steel Holding Corporation\nU.S. District Court: Eastern District of MichiganSORL Auto Parts, Inc.\nU.S. District Court: Southern District of New YorkAircastle Limited\nU.S. District Court: Southern District of New YorkSlack Technologies, Inc. (NYSE: WORK)\nU.S. Court of Appeals: Ninth CircuitEmpire Resorts, Inc.\nCourt of Chancery of the State of DelawareVitamin Shoppe, Inc.\nCourt of Chancery of the State of DelawareCarrizo Oil & Gas, Inc.\nU.S. District Court: Southern District of New YorkHighpower International, Inc.\nIsramco, Inc.\nAkers Biosciences, Inc. (AKER)\nAlnylam Pharmaceuticals, Inc. (ALNY)\nZebra Technologies Corporation\nU.S. District Court: District of Northen IllinoisOSI Systems, Inc. (NASDAQ: OSIS)\nU.S. District Court: Central CaliforniaAqua Metals, Inc. (NASDAQ: AQMS)\nU.S. District Court: District of DelawareEquifax Inc. (EFX)\nU.S. District Court: Northern GeorgiaNews\nInvestors Reach a $12 Million Settlement in NantKwest Stock Drop Lawsuit\nBragar Eagel & Squire, P.C. announces that it has filed papers with the United States District Court to approve a $12 million settlement of a shareholder class action alleging that NantKwest failed to disclose tens of millions of dollars of executive compensation prior to its 2015 initial public offering. Bragar Eagel & Squire, P.C., and its co-counsel have vigorously litigated this action on behalf of the class for over two years.\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nBragar Eagel & Squire, P.C. appointed Lead Counsel in Shah v. A10 Networks, Inc. et al.\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nBragar Eagel & Squire, P.C. appointed Lead Counsel in Xu v. Gridsum Holding Inc. et al., No. 18 Civ. 3655\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nU.S. District Court Judge Richard Seeborg of the United States District Court for the Northern District of California denied Charles Schwab\u2019s motion to dismiss in Crago v. Charles Schwab & Co., Inc\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nU.S. District Judge Michael W. Fitzgerald of the United States District Court for the Central District of California denies NantKwest\u2019s motion to dismiss in Sudunagunta v. NantKwest, Inc\nFor additional information, please contact Brandon Walker, Esq. at (212) 308-5858.\nBragar Eagel & Squire, P.C. appointed Co-Lead Counsel in the action Sudunagunta v. NantKwest, Inc.\nFor additional information, please contact Brandon Walker, Esq. at (212) 355-4648.\nPrior results do not guarantee a similar outcome.\nBragar Eagel & Squire, P.C. appointed Co-Lead Counsel in McCloskey v. Match Group, Inc.\nFor additional information, please contact Brandon Walker, Esq. at (212) 355-4648.\nPrior results do not guarantee a similar outcome."
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=PFP8o6LBliGRHaB41JUftkOY4u-rP9e0Do-ZrsD2oUI_l5XTF2PAhGDOxK40kqXGLrj_FwHcBAuUxO1Phk36XA==",
      "text": "Court Approves Settlement, Align Technology, Inc. to Implement Key Reforms\nBragar Eagel & Squire, P.C. is excited to share news of a settlement on behalf of Align Technology, Inc.'s shareholders. Today, February 5, 2025, United States District Court Judge Trina L. Thompson approved the global settlement as final. This is the result of extensive negotiations by Bragar Eagel & Squire, P.C., together with co-counsel. The settlement will require key corporate governance reforms, including adding an independent director with cybersecurity expertise to the Board, enhanced Board trainings, and enhanced regulatory compliance and compliance oversight functions. These reforms should help protect the Align Technology, Inc.\u2019s investors in the future.\n*Past results do not guarantee future outcomes.\nLinkedIn"
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=Vbw4BPWSSR5hKZXlCW6ChPv_i91Lb-V7dx6BqpoLkrCivBCq4FjDZzc-yOu6eYI4F1Pz62wxBoPNRz_zkqIZAkeZ6Z3adpinqfWrlKJbS2Y=",
      "text": "Court Approves Settlement, Align Technology, Inc. to Implement Key Reforms\nBragar Eagel & Squire, P.C. is excited to share news of a settlement on behalf of Align Technology, Inc.'s shareholders. Today, February 5, 2025, United States District Court Judge Trina L. Thompson approved the global settlement as final. This is the result of extensive negotiations by Bragar Eagel & Squire, P.C., together with co-counsel. The settlement will require key corporate governance reforms, including adding an independent director with cybersecurity expertise to the Board, enhanced Board trainings, and enhanced regulatory compliance and compliance oversight functions. These reforms should help protect the Align Technology, Inc.\u2019s investors in the future.\n*Past results do not guarantee future outcomes.\nLinkedIn"
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=s6XdkFVi0-s4fCa6OBfhFUhgHUI0D2AkKEF48bafgcEtlF6STZS8TT8DoJt3jDMwvgbpSuGjn4DnZHq1Tl6ZFA==",
      "text": "Cases\nPraxis Precision Medicines, Inc.\nSecurities Class Action\nOverview\nOverview\n- Date:\n- 8/22/2025\n- Company Name:\n- Praxis Precision Medicines, Inc.\n- Stock Symbol:\n- PRAX\n- Status:\n- Investigating\nBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (\u201cPraxis\u201d or the \u201cCompany\u201d) (NASDAQ:PRAX) on behalf of Praxis stockholders. Our investigation concerns whether Praxis has violated the federal securities laws and/or engaged in other unlawful business practices.\nOn August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study.\nOn this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025.\nIf you purchased or otherwise acquired Praxis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.\nOn August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study.\nOn this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025.\nIf you purchased or otherwise acquired Praxis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.\nContact Instructions\nPlease contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions regarding the case.\nThe individual or institution below (\u201cPlaintiff\u201d) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (\u201cBESPC\u201d) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff\u2019s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Praxis Precision Medicines. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.\nCase Updates\nRetainer Agreement\nThis will confirm that you have retained Bragar Eagel & Squire, P.C. (\u201cBESPC\u201d) to represent you in connection with potential litigation against Praxis Precision Medicines (the \u201cCompany\u201d) and its directors and officers. BESPC has conducted an investigation and believes that there is a valid basis to assert claims against the Company and its directors and/or officers for violation of federal or state securities laws.\nIn making this agreement, BESPC is relying upon your representation that you purchased the Company\u2019s shares during the period from (the \u201cRelevant Period\u201d). Please provide us with documentation of your trading history in the Company\u2019s stock by emailing a relevant copies of your brokerage statements to investigations@bespc.com. If you have any questions or need assistance, please call us at (212) 308-5858.\nThe terms under which we will represent you and your responsibilities as a potential representative plaintiff are set forth below.\nYou will have an obligation to remain knowledgeable about the litigation and participate in decisions concerning the progress of the litigation. If BESPC is appointed as lead counsel or in a similar capacity in the action, we will provide you with copies of all pleadings in the litigation for your review and approval, circumstances permitting, before they are filed with the court. BESPC will also promptly advise you of any significant developments in the litigation.\nAs a representative plaintiff, you cannot have any interest antagonistic to or in conflict with other Class members or the Company, as applicable, concerning the claims we are pursuing or any relationships with any of the named defendants that would in any way impair your ability or incentive to obtain the best possible result. You agree that neither you nor any of your affiliates or agents will trade stocks while in the possession of any material non-public information you may receive in connection with the litigation. In addition, as a representative plaintiff, you may be required to continue holding Company shares. Please contact us before buying or selling Company shares.\nBESPC may associate with other counsel to assist in the prosecution of this litigation. Any recovery of fees and costs will be shared with such counsel, determined on a percentage basis or based upon the time spent on the matter, as approved by the court if applicable. The division of work and or fees among co-counsel will not affect the amount of fees received upon a successful completion of the litigation. From time to time, BESPC may utilize contract attorneys to supplement the work of its own employed attorneys. BESPC will supervise the work of all contract attorneys and adopt their work product as its own. You authorize BESPC, as we deem appropriate, to associate with other counsel and to hire experts and consultants to assist in the handling of your claims.\nIt is possible that you will not be appointed as a lead plaintiff or class representative in the action. However, we may wish to represent you in other litigation related to the wrongful acts giving rise to this case. In such event, we will contact you to discuss the scope of such representation and obtain your approval before moving forward. You also agree that we may contact you with respect to other potential matters on your behalf.\nYou understand that in the event we secure a recovery for a Class in a class action, you will only be entitled to your proportional share of such recovery as a Class member. You understand that you will not receive any special treatment or receive a greater share of any class-wide recovery based on your service as a named plaintiff or class representative. However, we may ask the Court to approve an additional award to you to compensate you for the time and effort you expend on this matter. Any such award is solely within the discretion of the Court.\nBESPC will consult with you regarding any settlement negotiations and seek to obtain your approval for any proposed resolution of this litigation before entering into a final settlement agreement with defendants.\nYou expressly acknowledge that we have not made any representation to you, express or implied, concerning the outcome of any litigation or other matter in which we represent you.\nIf you are not chosen as a representative plaintiff and we do not choose to pursue other related litigation on your behalf, we will provide you with notification and this Agreement shall terminate. Otherwise, this Agreement shall remain in effect until the conclusion of the relevant litigation. However, you may terminate this Agreement at any time.\nUpon termination, BESPC\u2019s files and papers compiled in connection with its investigation and prosecution of this matter constitute the work product and property of BESPC over which it has complete control with respect to its use and/or disclosure.\nThis agreement sets forth the entire agreement between the parties and supersedes all other oral or written communications.\nPlease feel free to contact us at any time should you have any questions or comments in this regard.\nIn making this agreement, BESPC is relying upon your representation that you purchased the Company\u2019s shares during the period from (the \u201cRelevant Period\u201d). Please provide us with documentation of your trading history in the Company\u2019s stock by emailing a relevant copies of your brokerage statements to investigations@bespc.com. If you have any questions or need assistance, please call us at (212) 308-5858.\nThe terms under which we will represent you and your responsibilities as a potential representative plaintiff are set forth below.\nYour Responsibilities as a Representative Plaintiff\nAs a representative plaintiff, you will have a duty to represent the interests of similarly situated shareholders, i.e., the \u201cClass,\u201d and to participate in the prosecution of this litigation. You may also be asked to provide documents concerning your trading in Company stock and may be asked to sit for a deposition. Accordingly, you should preserve all documents that relate to this case until it has concluded or we inform you otherwise. Relevant documents include any information you have about the Company or your trading in Company stock, no matter how it is recorded or who is keeping it for you. If you have any questions about whether information should be retained, please contact us.You will have an obligation to remain knowledgeable about the litigation and participate in decisions concerning the progress of the litigation. If BESPC is appointed as lead counsel or in a similar capacity in the action, we will provide you with copies of all pleadings in the litigation for your review and approval, circumstances permitting, before they are filed with the court. BESPC will also promptly advise you of any significant developments in the litigation.\nAs a representative plaintiff, you cannot have any interest antagonistic to or in conflict with other Class members or the Company, as applicable, concerning the claims we are pursuing or any relationships with any of the named defendants that would in any way impair your ability or incentive to obtain the best possible result. You agree that neither you nor any of your affiliates or agents will trade stocks while in the possession of any material non-public information you may receive in connection with the litigation. In addition, as a representative plaintiff, you may be required to continue holding Company shares. Please contact us before buying or selling Company shares.\nContingency Fee and Advancement of Expenses\nBESPC will prosecute this litigation on a contingency basis. You will not be responsible for paying any legal fees, costs, or out-of-pocket expenses arising out of or related to the prosecution of this litigation, regardless of the outcome of the matter. If there is a monetary recovery in this action, BESPC will, at the conclusion of the litigation or any segment thereof, apply to the court for approval of an award of attorneys\u2019 fees and reimbursement of expenses. BESPC may also seek a fee if we obtain substantial non-monetary relief for the Class or the Company. The court will then award fees and disbursements (if any) from the proceeds of any judgment or settlement obtained in this litigation, based on factors considered relevant by the court. Such fees, costs, and disbursements will be paid from the entire settlement amount and not only from your share of the settlement amount.\nAssociation with Counsel\nBESPC may associate with other counsel to assist in the prosecution of this litigation. Any recovery of fees and costs will be shared with such counsel, determined on a percentage basis or based upon the time spent on the matter, as approved by the court if applicable. The division of work and or fees among co-counsel will not affect the amount of fees received upon a successful completion of the litigation. From time to time, BESPC may utilize contract attorneys to supplement the work of its own employed attorneys. BESPC will supervise the work of all contract attorneys and adopt their work product as its own. You authorize BESPC, as we deem appropriate, to associate with other counsel and to hire experts and consultants to assist in the handling of your claims.\nOther Actions\nIt is possible that you will not be appointed as a lead plaintiff or class representative in the action. However, we may wish to represent you in other litigation related to the wrongful acts giving rise to this case. In such event, we will contact you to discuss the scope of such representation and obtain your approval before moving forward. You also agree that we may contact you with respect to other potential matters on your behalf.\nNo Special Treatment\nYou understand that in the event we secure a recovery for a Class in a class action, you will only be entitled to your proportional share of such recovery as a Class member. You understand that you will not receive any special treatment or receive a greater share of any class-wide recovery based on your service as a named plaintiff or class representative. However, we may ask the Court to approve an additional award to you to compensate you for the time and effort you expend on this matter. Any such award is solely within the discretion of the Court.\nSettlement\nBESPC will consult with you regarding any settlement negotiations and seek to obtain your approval for any proposed resolution of this litigation before entering into a final settlement agreement with defendants.\nNo Guarantee of Success\nYou expressly acknowledge that we have not made any representation to you, express or implied, concerning the outcome of any litigation or other matter in which we represent you.\nTermination of This Agreement\nIf you are not chosen as a representative plaintiff and we do not choose to pursue other related litigation on your behalf, we will provide you with notification and this Agreement shall terminate. Otherwise, this Agreement shall remain in effect until the conclusion of the relevant litigation. However, you may terminate this Agreement at any time. Upon termination, BESPC\u2019s files and papers compiled in connection with its investigation and prosecution of this matter constitute the work product and property of BESPC over which it has complete control with respect to its use and/or disclosure.\nThis agreement sets forth the entire agreement between the parties and supersedes all other oral or written communications.\nPlease feel free to contact us at any time should you have any questions or comments in this regard."
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=YN9YpfxOyLCgQ-zdWZzSlvJv2E12vkXnQAc0QzsyEViGNHLSbE92Q7Oph9I_8aKvqZwuapgIzNgFX3_sKEjp6ByvDSpRVf7xNyeIyC42PsSzFTximz9woWm7Etq5XUP5",
      "text": "Cases\nPraxis Precision Medicines, Inc.\nSecurities Class Action\nOverview\nOverview\n- Date:\n- 8/22/2025\n- Company Name:\n- Praxis Precision Medicines, Inc.\n- Stock Symbol:\n- PRAX\n- Status:\n- Investigating\nBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (\u201cPraxis\u201d or the \u201cCompany\u201d) (NASDAQ:PRAX) on behalf of Praxis stockholders. Our investigation concerns whether Praxis has violated the federal securities laws and/or engaged in other unlawful business practices.\nOn August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study.\nOn this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025.\nIf you purchased or otherwise acquired Praxis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.\nOn August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study.\nOn this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025.\nIf you purchased or otherwise acquired Praxis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.\nContact Instructions\nPlease contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions regarding the case.\nThe individual or institution below (\u201cPlaintiff\u201d) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (\u201cBESPC\u201d) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff\u2019s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Praxis Precision Medicines. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.\nCase Updates\nRetainer Agreement\nThis will confirm that you have retained Bragar Eagel & Squire, P.C. (\u201cBESPC\u201d) to represent you in connection with potential litigation against Praxis Precision Medicines (the \u201cCompany\u201d) and its directors and officers. BESPC has conducted an investigation and believes that there is a valid basis to assert claims against the Company and its directors and/or officers for violation of federal or state securities laws.\nIn making this agreement, BESPC is relying upon your representation that you purchased the Company\u2019s shares during the period from (the \u201cRelevant Period\u201d). Please provide us with documentation of your trading history in the Company\u2019s stock by emailing a relevant copies of your brokerage statements to investigations@bespc.com. If you have any questions or need assistance, please call us at (212) 308-5858.\nThe terms under which we will represent you and your responsibilities as a potential representative plaintiff are set forth below.\nYou will have an obligation to remain knowledgeable about the litigation and participate in decisions concerning the progress of the litigation. If BESPC is appointed as lead counsel or in a similar capacity in the action, we will provide you with copies of all pleadings in the litigation for your review and approval, circumstances permitting, before they are filed with the court. BESPC will also promptly advise you of any significant developments in the litigation.\nAs a representative plaintiff, you cannot have any interest antagonistic to or in conflict with other Class members or the Company, as applicable, concerning the claims we are pursuing or any relationships with any of the named defendants that would in any way impair your ability or incentive to obtain the best possible result. You agree that neither you nor any of your affiliates or agents will trade stocks while in the possession of any material non-public information you may receive in connection with the litigation. In addition, as a representative plaintiff, you may be required to continue holding Company shares. Please contact us before buying or selling Company shares.\nBESPC may associate with other counsel to assist in the prosecution of this litigation. Any recovery of fees and costs will be shared with such counsel, determined on a percentage basis or based upon the time spent on the matter, as approved by the court if applicable. The division of work and or fees among co-counsel will not affect the amount of fees received upon a successful completion of the litigation. From time to time, BESPC may utilize contract attorneys to supplement the work of its own employed attorneys. BESPC will supervise the work of all contract attorneys and adopt their work product as its own. You authorize BESPC, as we deem appropriate, to associate with other counsel and to hire experts and consultants to assist in the handling of your claims.\nIt is possible that you will not be appointed as a lead plaintiff or class representative in the action. However, we may wish to represent you in other litigation related to the wrongful acts giving rise to this case. In such event, we will contact you to discuss the scope of such representation and obtain your approval before moving forward. You also agree that we may contact you with respect to other potential matters on your behalf.\nYou understand that in the event we secure a recovery for a Class in a class action, you will only be entitled to your proportional share of such recovery as a Class member. You understand that you will not receive any special treatment or receive a greater share of any class-wide recovery based on your service as a named plaintiff or class representative. However, we may ask the Court to approve an additional award to you to compensate you for the time and effort you expend on this matter. Any such award is solely within the discretion of the Court.\nBESPC will consult with you regarding any settlement negotiations and seek to obtain your approval for any proposed resolution of this litigation before entering into a final settlement agreement with defendants.\nYou expressly acknowledge that we have not made any representation to you, express or implied, concerning the outcome of any litigation or other matter in which we represent you.\nIf you are not chosen as a representative plaintiff and we do not choose to pursue other related litigation on your behalf, we will provide you with notification and this Agreement shall terminate. Otherwise, this Agreement shall remain in effect until the conclusion of the relevant litigation. However, you may terminate this Agreement at any time.\nUpon termination, BESPC\u2019s files and papers compiled in connection with its investigation and prosecution of this matter constitute the work product and property of BESPC over which it has complete control with respect to its use and/or disclosure.\nThis agreement sets forth the entire agreement between the parties and supersedes all other oral or written communications.\nPlease feel free to contact us at any time should you have any questions or comments in this regard.\nIn making this agreement, BESPC is relying upon your representation that you purchased the Company\u2019s shares during the period from (the \u201cRelevant Period\u201d). Please provide us with documentation of your trading history in the Company\u2019s stock by emailing a relevant copies of your brokerage statements to investigations@bespc.com. If you have any questions or need assistance, please call us at (212) 308-5858.\nThe terms under which we will represent you and your responsibilities as a potential representative plaintiff are set forth below.\nYour Responsibilities as a Representative Plaintiff\nAs a representative plaintiff, you will have a duty to represent the interests of similarly situated shareholders, i.e., the \u201cClass,\u201d and to participate in the prosecution of this litigation. You may also be asked to provide documents concerning your trading in Company stock and may be asked to sit for a deposition. Accordingly, you should preserve all documents that relate to this case until it has concluded or we inform you otherwise. Relevant documents include any information you have about the Company or your trading in Company stock, no matter how it is recorded or who is keeping it for you. If you have any questions about whether information should be retained, please contact us.You will have an obligation to remain knowledgeable about the litigation and participate in decisions concerning the progress of the litigation. If BESPC is appointed as lead counsel or in a similar capacity in the action, we will provide you with copies of all pleadings in the litigation for your review and approval, circumstances permitting, before they are filed with the court. BESPC will also promptly advise you of any significant developments in the litigation.\nAs a representative plaintiff, you cannot have any interest antagonistic to or in conflict with other Class members or the Company, as applicable, concerning the claims we are pursuing or any relationships with any of the named defendants that would in any way impair your ability or incentive to obtain the best possible result. You agree that neither you nor any of your affiliates or agents will trade stocks while in the possession of any material non-public information you may receive in connection with the litigation. In addition, as a representative plaintiff, you may be required to continue holding Company shares. Please contact us before buying or selling Company shares.\nContingency Fee and Advancement of Expenses\nBESPC will prosecute this litigation on a contingency basis. You will not be responsible for paying any legal fees, costs, or out-of-pocket expenses arising out of or related to the prosecution of this litigation, regardless of the outcome of the matter. If there is a monetary recovery in this action, BESPC will, at the conclusion of the litigation or any segment thereof, apply to the court for approval of an award of attorneys\u2019 fees and reimbursement of expenses. BESPC may also seek a fee if we obtain substantial non-monetary relief for the Class or the Company. The court will then award fees and disbursements (if any) from the proceeds of any judgment or settlement obtained in this litigation, based on factors considered relevant by the court. Such fees, costs, and disbursements will be paid from the entire settlement amount and not only from your share of the settlement amount.\nAssociation with Counsel\nBESPC may associate with other counsel to assist in the prosecution of this litigation. Any recovery of fees and costs will be shared with such counsel, determined on a percentage basis or based upon the time spent on the matter, as approved by the court if applicable. The division of work and or fees among co-counsel will not affect the amount of fees received upon a successful completion of the litigation. From time to time, BESPC may utilize contract attorneys to supplement the work of its own employed attorneys. BESPC will supervise the work of all contract attorneys and adopt their work product as its own. You authorize BESPC, as we deem appropriate, to associate with other counsel and to hire experts and consultants to assist in the handling of your claims.\nOther Actions\nIt is possible that you will not be appointed as a lead plaintiff or class representative in the action. However, we may wish to represent you in other litigation related to the wrongful acts giving rise to this case. In such event, we will contact you to discuss the scope of such representation and obtain your approval before moving forward. You also agree that we may contact you with respect to other potential matters on your behalf.\nNo Special Treatment\nYou understand that in the event we secure a recovery for a Class in a class action, you will only be entitled to your proportional share of such recovery as a Class member. You understand that you will not receive any special treatment or receive a greater share of any class-wide recovery based on your service as a named plaintiff or class representative. However, we may ask the Court to approve an additional award to you to compensate you for the time and effort you expend on this matter. Any such award is solely within the discretion of the Court.\nSettlement\nBESPC will consult with you regarding any settlement negotiations and seek to obtain your approval for any proposed resolution of this litigation before entering into a final settlement agreement with defendants.\nNo Guarantee of Success\nYou expressly acknowledge that we have not made any representation to you, express or implied, concerning the outcome of any litigation or other matter in which we represent you.\nTermination of This Agreement\nIf you are not chosen as a representative plaintiff and we do not choose to pursue other related litigation on your behalf, we will provide you with notification and this Agreement shall terminate. Otherwise, this Agreement shall remain in effect until the conclusion of the relevant litigation. However, you may terminate this Agreement at any time. Upon termination, BESPC\u2019s files and papers compiled in connection with its investigation and prosecution of this matter constitute the work product and property of BESPC over which it has complete control with respect to its use and/or disclosure.\nThis agreement sets forth the entire agreement between the parties and supersedes all other oral or written communications.\nPlease feel free to contact us at any time should you have any questions or comments in this regard."
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=yk3_iI07jkXLeQQsxmreAXm7hJPKzYHtL9qQyQc9GJIDs6EGZsiMNU_Mm_mJbag2HaJJT6x0wX-GSvyslR-df453-sPTfqgicMfHELfLLxH6nSkAJkqpP9JTq3tacIij",
      "text": "Bio\nLegal Career\n2017-2018 Levi & Korsinsky LLP2013-2017 Stutz & Passmore PLLC\n2004-2013 Bernstein Litowitz Berger & Grossmann LLP\nAreas of Practice\nMarion has a broad litigation practice, with an extensive background in securities litigation. She has prosecuted numerous securities fraud actions on behalf of institutional and individual investors. Prior to joining BESPC, she co-founded a small private practice that specialized in estate planning and probate actions, civil litigation, real property, and served as city attorney for the City of Choteau, Montana.Professional Activities and Associations\n- California State Bar Association\n- Montana State Bar Association\nExperience\n- Abouzied v. Applied Opotelectronics, Inc., et al., Case No. 17-cv-02399 (S.D. Tex.). Securities fraud class action challenging alleged false and misleading statements relating to, among other things, Applied Opotelectronics\u2019 continuing demand from Amazon, its largest customer.\n- In re Insys Therapeutics, Inc. Sec. Litig., Case No. 17-cv-01954-PAC (S.D.N.Y.). Securities fraud class action challenging alleged false and misleading statements relating to Insys\u2019s revenue recognition, sales allowances, accounting policies, and internal controls, necessitating a restatement of the company\u2019s financial statements.\n- In re Toyota Motor Corp. Sec. Litig., Case No. 10-922 DSF (AKWx) (C.D. Cal.). Securities fraud class action challenging alleged false and misleading statements relating to the quality and safety of Toyota vehicles.\n- In re Lehman Brothers Equity/Debt Sec. Litig., Case No. 08-5523, 09-md-2017 (LAK) (S.D.N.Y.). Securities fraud class action challenging various debt and equity offerings containing alleged false and misleading statements relating to, among other things, repurchase and resale transactions, risk management, and credit risk.\n- In re Washington Mutual Sec. Litig., Case No. 08-md-1919 MJP (W.D. Wash.). Securities fraud action challenging alleged false and misleading statements regarding WaMu\u2019s loan appraisal and underwriting practices, accounting practices, and internal controls.\n- In re Stone Energy Corp. Sec. Litig., Case No. 05-cv-2088 (E.D. Tex.). Securities fraud action challenging alleged false and misleading statements regarding Stone\u2019s oil and gas reserves resulting in misleading financial statements.\n- In re Mutual Funds Investment Litigation \u2013 Invesco, Case No. 04-md-15864 (D. Md.), MFS, Case No. 04-md-15863 (D. Md.), Pilgrim Baxter, Case No. 04-md-15862 (D. Md.). Securities fraud actions alleging undisclosed market timing which negatively impacted the mutual funds causing losses to investors in the funds.\n- In re El Paso Corp. Sec. Litig., 02-cv-2717 (S.D. Tex.). Securities fraud class action challenging alleged false and misleading statements regarding El Paso\u2019s revenues as a result of round trip trading, mark to market accounting, and overstated oil and gas reserves, as well as manipulation of the California energy market."
    }
  ],
  "argos_summary": "Bragar Eagel & Squire, P.C. is investigating potential securities law violations by Praxis Precision Medicines, Inc. after the company\u2019s August 4, 2025 Q2 earnings release revealed high rates of adverse events in a mid\u2011stage study of its anti\u2011seizure drug, causing the stock to fall 5.55%. The firm is offering to represent shareholders who suffered losses, providing a contingency\u2011basis retainer and encouraging them to contact partner Brandon Walker or Marion Passmore for legal assistance. The announcement also includes brief updates on other firm activities, such as a settlement with Align Technology and new hires, but the primary focus is the Praxis investigation and shareholder support.",
  "argos_id": "1VXDYWBMD"
}